BR112015028025A8 - composição farmacêutica adaptada para administração oral e uso de uma composição - Google Patents

composição farmacêutica adaptada para administração oral e uso de uma composição Download PDF

Info

Publication number
BR112015028025A8
BR112015028025A8 BR112015028025A BR112015028025A BR112015028025A8 BR 112015028025 A8 BR112015028025 A8 BR 112015028025A8 BR 112015028025 A BR112015028025 A BR 112015028025A BR 112015028025 A BR112015028025 A BR 112015028025A BR 112015028025 A8 BR112015028025 A8 BR 112015028025A8
Authority
BR
Brazil
Prior art keywords
oral administration
composition
pharmaceutical composition
composition adapted
adrenal
Prior art date
Application number
BR112015028025A
Other languages
English (en)
Other versions
BR112015028025B1 (pt
BR112015028025A2 (pt
Inventor
Grave Annette
Huatan Hiep
Whitaker Martin
Poellinger Norbert
Ross Richard
Original Assignee
Diurnal Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diurnal Ltd filed Critical Diurnal Ltd
Publication of BR112015028025A2 publication Critical patent/BR112015028025A2/pt
Publication of BR112015028025A8 publication Critical patent/BR112015028025A8/pt
Publication of BR112015028025B1 publication Critical patent/BR112015028025B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1 / 1 resumo “composiã‡ãƒo farmacãšutica adaptada para administraã‡ãƒo oral e regime de tratamento para o controle de insuficiãšncia adrenal” a descriã§ã£o se refere a composiã§ãµes farmacãªuticas ãºteis no tratamento de insuficiãªncia adrenal em indivã­duos pediã¡tricos ou idosos.
BR112015028025-0A 2013-05-17 2014-05-12 Composição farmacêutica adaptada para administração oral e uso de uma composição BR112015028025B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1308933.9A GB201308933D0 (en) 2013-05-17 2013-05-17 Paediatric composition
GB1308933.9 2013-05-17
PCT/GB2014/051442 WO2014184525A1 (en) 2013-05-17 2014-05-12 Composition comprising hydrocortisone

Publications (3)

Publication Number Publication Date
BR112015028025A2 BR112015028025A2 (pt) 2017-07-25
BR112015028025A8 true BR112015028025A8 (pt) 2019-12-31
BR112015028025B1 BR112015028025B1 (pt) 2022-11-29

Family

ID=48746932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028025-0A BR112015028025B1 (pt) 2013-05-17 2014-05-12 Composição farmacêutica adaptada para administração oral e uso de uma composição

Country Status (25)

Country Link
US (1) US9649280B2 (pt)
EP (1) EP2978414B1 (pt)
JP (1) JP6371379B2 (pt)
KR (1) KR102219919B1 (pt)
CN (1) CN105120848B (pt)
AU (1) AU2014267041B2 (pt)
BR (1) BR112015028025B1 (pt)
CA (1) CA2909060C (pt)
CY (1) CY1123284T1 (pt)
DK (1) DK2978414T3 (pt)
ES (1) ES2813382T3 (pt)
GB (2) GB201308933D0 (pt)
HK (1) HK1214131A1 (pt)
HR (1) HRP20201315T1 (pt)
HU (1) HUE050917T2 (pt)
IL (1) IL242275B (pt)
LT (1) LT2978414T (pt)
MX (1) MX2015015759A (pt)
PL (1) PL2978414T3 (pt)
PT (1) PT2978414T (pt)
RS (1) RS60734B1 (pt)
RU (1) RU2664678C2 (pt)
SI (1) SI2978414T1 (pt)
WO (1) WO2014184525A1 (pt)
ZA (1) ZA201507210B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
US20190180872A1 (en) * 2017-12-12 2019-06-13 International Business Machines Corporation Second Opinion Decision Support Using Patient Electronic Medical Records

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69101291T2 (de) 1990-08-30 1994-07-07 Senju Pharma Co Zusammensetzung zur kontrollierten Abgabe von Medikamenten.
EP0876142B1 (en) 1996-01-16 2001-09-26 Advanced Polymer Systems, Inc. Topical delivery of drugs to the lower gastrointestinal tract
KR20040016202A (ko) * 2002-08-16 2004-02-21 주식회사 제이알팜 쓴맛이 차폐된 히드로코르티손 경구용 약제 조성물 및 그제조방법
AU2005235369B2 (en) 2004-04-22 2010-11-11 Acucort Ab Pharmaceutical compositions for acute glucocorticoid therapy
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
EP1787640A4 (en) * 2004-04-30 2012-04-11 Astellas Pharma Inc GRAINED PHARMACEUTICAL COMPOSITION WITH TEMPORARY DELIVERY FOR ORAL ADMINISTRATION AND FAST-DECREASING INTRAORAL TABLET WITH THE COMPOSITION
MXPA06013849A (es) * 2004-05-31 2007-03-01 Almirall Lab Combinaciones que comprenden agentes antimuscarinicos e inhibidores de pde4.
US20070281007A1 (en) * 2004-08-27 2007-12-06 Jacob Jules S Mucoadhesive Oral Formulations of High Permeability, High Solubility Drugs
RU2290940C2 (ru) * 2004-10-18 2007-01-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская Государственная Медицинская академия" МЗ РФ (ГОУ ВПО НижГМА) Средство для коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом, и способ коррекции острой почечной недостаточности при токсическом гепаторенальном синдроме, индуцированном четыреххлористым углеродом
US20060292214A1 (en) * 2005-06-03 2006-12-28 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
WO2008126076A2 (en) * 2007-04-11 2008-10-23 Perrigo Israel Pharmaceuticals Ltd. Low-dose mometasone formulations
GB0817120D0 (en) 2008-09-19 2008-10-29 Diurnal Ltd Treatment of adrenal insufficiency
MX2011010525A (es) 2009-04-07 2012-04-02 Duocort Pharma Ab Terapia mejorada con glucocorticoides.
MY171317A (en) * 2009-10-01 2019-10-08 Adare Pharmaceuticals Inc Orally administered corticosteroid compositions
KR101765357B1 (ko) * 2009-12-02 2017-08-04 아데어 파마수티컬스 에스.알.엘. 펙소페나딘 마이크로캡슐 및 그것을 함유하는 조성물
CA2799820A1 (en) 2010-05-20 2011-11-24 Duocort Pharma Ab Posology and administration of glucocorticoid based compositions
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Also Published As

Publication number Publication date
JP6371379B2 (ja) 2018-08-08
CN105120848A (zh) 2015-12-02
DK2978414T3 (da) 2020-08-24
JP2016518439A (ja) 2016-06-23
US9649280B2 (en) 2017-05-16
RU2015150303A3 (pt) 2018-03-26
PT2978414T (pt) 2020-08-27
BR112015028025B1 (pt) 2022-11-29
NZ712756A (en) 2020-12-18
GB201516973D0 (en) 2015-11-11
ZA201507210B (en) 2017-07-26
LT2978414T (lt) 2020-09-25
RU2015150303A (ru) 2017-06-22
EP2978414A1 (en) 2016-02-03
CA2909060C (en) 2020-03-10
BR112015028025A2 (pt) 2017-07-25
CA2909060A1 (en) 2014-11-20
KR20160011205A (ko) 2016-01-29
PL2978414T3 (pl) 2020-11-16
ES2813382T3 (es) 2021-03-23
CY1123284T1 (el) 2021-12-31
HUE050917T2 (hu) 2021-01-28
HK1214131A1 (zh) 2016-07-22
WO2014184525A1 (en) 2014-11-20
CN105120848B (zh) 2019-06-04
HRP20201315T1 (hr) 2020-11-27
RU2664678C2 (ru) 2018-08-21
IL242275B (en) 2018-08-30
KR102219919B1 (ko) 2021-02-25
GB201308933D0 (en) 2013-07-03
MX2015015759A (es) 2016-03-15
RS60734B1 (sr) 2020-09-30
GB2527233A (en) 2015-12-16
US20160081942A1 (en) 2016-03-24
AU2014267041B2 (en) 2018-11-22
SI2978414T1 (sl) 2020-10-30
EP2978414B1 (en) 2020-07-22
GB2527233B (en) 2017-07-05
AU2014267041A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
BR112015015870A8 (pt) composição farmacêutica, e, uso de uma composição farmacêutica
CL2016001547A1 (es) Composiciones para el cuidado oral
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
CL2015003117A1 (es) Modificaciones en la estructura cristalina
MY196173A (en) Cot Modulators And Methods Of Use Thereof
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
BR112016003229A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
SV2015004969A (es) Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
PE20151778A1 (es) Formulacion combinada de dos compuestos antivirales
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
BR112015031417A2 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
BR112016029013A2 (pt) aperfeiçoamento em composição nasal e método de utilização do mesmo
UY35344A (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
BR112013016590A2 (pt) uso de estabilizantes de glutamina
BR112016028518A2 (pt) composições farmacêuticas que compreendem dgla e uso do mesmo
CY1123284T1 (el) Συνθεση που περιλαμβανει υδροκορτιζονη
DOP2015000089A (es) Composición de difenidol de liberación prolongada
CL2017000884A1 (es) Composición farmacéutica para usarse en el tratamiento o la prevención de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugía de derivación gástrica
BR112016006624B8 (pt) formulação de creme dental
BR112015014262A8 (pt) formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica
CL2016000397A1 (es) Tratamiento contra el cáncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/05/2014, OBSERVADAS AS CONDICOES LEGAIS